{
    "Trade/Device Name(s)": [
        "Ascensia\u00ae BREEZE\u00ae2 Blood Glucose Monitoring System"
    ],
    "Submitter Information": "Bayer HealthCare, Diabetes Care",
    "510(k) Number": "K062347",
    "Predicate Device Reference 510(k) Number(s)": [
        "K024062"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NBW",
        "CGA",
        "JJX"
    ],
    "Summary Letter Date": "November 15, 2006",
    "Summary Letter Received Date": "November 16, 2006",
    "Submission Date": "August 9, 2006",
    "Regulation Number(s)": [
        "21 CFR 862.1345"
    ],
    "Regulation Name(s)": [
        "Glucose test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Whole blood"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Ascensia\u00ae BREEZE\u00ae2 Blood Glucose Monitor"
    ],
    "Method(s)/Technology(ies)": [
        "Amperometric glucose oxidase method"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "Analyzer",
        "Reagent",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for Ascensia BREEZE 2 Blood Glucose Monitoring System using amperometric glucose oxidase technology for glucose measurement in whole blood",
    "Indications for Use Summary": "Over-the-counter blood glucose monitoring system for persons with diabetes, measuring glucose in whole blood from fingertip, palm, or forearm; not for use with neonatal specimens",
    "fda_folder": "Clinical Chemistry"
}